Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016
Published Jun 08, 2016
79 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease)
- The report reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pituitary ACTH Hypersecretion (Cushing Disease) therapeutics and enlists all their major and minor projects
- The report assesses Pituitary ACTH Hypersecretion (Cushing Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding t

  
Source:
Document ID
GMDHC8184IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Pituitary ACTH Hypersecretion (Cushing Disease) Overview81
Therapeutics Development92
  Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) Overview91
  Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) Comparative Analysis101
Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics under Development by Companies111
Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics under Investigation by Universities/Institutes121
Pituitary ACTH Hypersecretion (Cushing Disease) Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Pituitary ACTH Hypersecretion (Cushing Disease) Products under Development by Companies161
Pituitary ACTH Hypersecretion (Cushing Disease) Products under Investigation by Universities/Institutes171
Pituitary ACTH Hypersecretion (Cushing Disease) Companies Involved in Therapeutics Development1811
  Alder Biopharmaceuticals Inc.181
  Corcept Therapeutics Incorporated191
  Cyclacel Pharmaceuticals, Inc.201
  ElexoPharm GmbH211
  Ionis Pharmaceuticals, Inc.221
  Ipsen S.A.231
  Millendo Therapeutics, Inc.241
  Orphagen Pharmaceuticals, Inc.251
  Pfizer Inc.261
  Strongbridge Biopharma plc271
  XOMA Corporation281
Pituitary ACTH Hypersecretion (Cushing Disease) Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3824
  ALD-1613 - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  ATR-101 - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  BIM-23B065 - Drug Profile401
    Product Description401
    Mechanism of Action401
    R&D Progress401
  COR-005 - Drug Profile411
    Product Description411
    Mechanism of Action411
    R&D Progress413
  IONIS-GCCRRx - Drug Profile441
    Product Description441
    Mechanism of Action441
    R&D Progress441
  levoketoconazole - Drug Profile451
    Product Description451
    Mechanism of Action451
    R&D Progress452
  mifepristone - Drug Profile471
    Product Description471
    Mechanism of Action471
    R&D Progress473
  Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing Disease - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  MPP-482 - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress511
  osilodrostat phosphate - Drug Profile521
    Product Description521
    Mechanism of Action521
    R&D Progress522
  pasireotide ER - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress542
  seliciclib - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress562
  Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing Disease and Congenital Adrenal Hyperplasia - Drug Profile581
    Product Description581
    Mechanism of Action581
    R&D Progress581
  Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing Disease - Drug Profile591
    Product Description591
    Mechanism of Action591
    R&D Progress591
  Small Molecules to Inhibit CYP11B1 for Cushing Disease and Subclinical Hypercortisolism - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress601
  Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile611
    Product Description611
    Mechanism of Action611
    R&D Progress611
Pituitary ACTH Hypersecretion (Cushing Disease) Recent Pipeline Updates6211
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects731
Pituitary ACTH Hypersecretion (Cushing Disease) Product Development Milestones744
  Featured News &Press Releases741
    Apr 03, 2016: Alder Presents Preclinical Data for ALD1613 at ENDO 2016741
    Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing Disease, a Serious Endocrine Disorder741
    Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society s 97th Annual Meeting &Expo751
    Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014751
    Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014751
    Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014751
    Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting761
    Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial761
    Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing Syndrome771
    Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing Syndrome771
Appendix782
  Methodology781
  Coverage781
  Secondary Research781
  Primary Research781
  Expert Panel Validation781
  Contact Us781
  Disclaimer791

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Pituitary-ACTH-Hypersecretion-Cushing-Disease-Pipeline-Review-H1-2016-2088-15916>
  
APA:
Global Markets Direct - Market Research. (2016). Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Pituitary-ACTH-Hypersecretion-Cushing-Disease-Pipeline-Review-H1-2016-2088-15916>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.